alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 32.1

           CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED
            PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned hereby certify,  pursuant to 18 U.S.C.  Section 1350, as adopted
pursuant  to  Section  906 of the  Sarbanes-Oxley  Act of 2002,  that the Annual
Report on Form 10-K/A for the period ended March 31, 2004 of Sport Chalet,  Inc.
(the "Company")  fully complies with the  requirements of Section 13(a) or 15(d)
of the  Securities  Exchange Act of 1934, as amended,  and that the  information
contained in such periodic report fairly presents, in all material respects, the
financial condition and results of operations of the Company as of, and for, the
periods presented in such report.

Date: June 6, 2005

                                     /s/   CRAIG L. LEVRA
                                     --------------------------------------
                                     Chairman of the Board, Chief Executive
                                     Officer and  President


                                     /s/   HOWARD K. KAMINSKY
                                     --------------------------------------
                                     Executive Vice President-Finance,
                                     Chief Financial Officer and Secretary

A signed  original of this  written  statement  required by Section 906 has been
provided  to Sport  Chalet,  Inc and will be  furnished  to the  Securities  and
Exchange Commission or its staff upon request.


                                       56
<PAGE>

                                  EXHIBIT 32.1

                               CERTIFICATION (1)

      Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities
Exchange Act of 1934, as amended (the "Exchange Act") and Section 1350 of
Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350), Emile
Loria, M.D., the Chief Executive Officer of Epimmune Inc. (the "Company"), and
Robert De Vaere, the Chief Financial Officer of the Company, each hereby
certifies that, to the best of his knowledge:

1. The Company's Quarterly Report on Form 10-Q for the period ended March 31,
2005, to which this Certification is attached as Exhibit 32.1 (the "Periodic
Report"), fully complies with the requirements of Section 13(a) or Section 15(d)
of the Exchange Act; and

2. The information contained in the Periodic Report fairly presents, in all
material respects, the financial condition of the Company at the end of the
period covered by the Periodic Report and results of operations of the Company
for the period covered by the Periodic Report.

Dated: May 13, 2005

/s/ Emile Loria                          /s/ Robert De Vaere
------------------------------------     -------------------------
Emile Loria, M.D.                        Robert De Vaere
President and Chief Executive Officer    Vice President, Finance and
                                         Administration and
                                         Chief Financial Officer

-----------------------------
(1) This certification accompanies the Form 10-Q to which it relates, is not
deemed filed with the Securities and Exchange Commission and is not to be
incorporated by reference into any filing of Epimmune Inc. under the Securities
Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended
(whether made before or after the date of the Form 10-Q), irrespective of any
general incorporation language contained in such filing.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS FOR HEARx LTD CONTAINED IN THE COMPANY'S REPORT ON FORM
10-Q AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<CIK> 0000821536
<NAME> HEARX LTD
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             DEC-26-1998
<PERIOD-END>                               APR-02-1999
<CASH>                                       2,253,231
<SECURITIES>                                 2,776,641
<RECEIVABLES>                                5,437,549
<ALLOWANCES>                                 (542,579)
<INVENTORY>                                  1,187,012
<CURRENT-ASSETS>                            11,111,854
<PP&E>                                      13,483,837
<DEPRECIATION>                             (6,858,665)
<TOTAL-ASSETS>                              21,070,007
<CURRENT-LIABILITIES>                        5,346,623
<BONDS>                                        120,316
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                     10,944
<COMMON>                                    10,781,839
<OTHER-SE>                                   4,821,228
<TOTAL-LIABILITY-AND-EQUITY>                21,070,007
<SALES>                                     10,454,525
<TOTAL-REVENUES>                            10,454,525
<CGS>                                        3,213,531
<TOTAL-COSTS>                                8,533,144
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                            (1,022,629)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (1,022,629)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                226,661
<CHANGES>                                            0
<NET-INCOME>                               (1,249,290)
<EPS-PRIMARY>                                  ($0.01)
<EPS-DILUTED>                                  ($0.01)
        

</TABLE>
#### Franklin Antonio BENJAMIN, Petitioner-Appellant, v. Willie EAGLETON, Warden, Evans Correctional Institution; Henry McMaster, Attorney General for South Carolina, Respondents-Appellees.

No. 06-6497.

United States Court of Appeals, Fourth Circuit.

Submitted: June 15, 2006.

Decided: June 21, 2006.

Franklin Antonio Benjamin, Appellant Pro Se. William Edgar Salter, III, Office of the Attorney General of South Carolina, Columbia, South Carolina, for Appellees.

Before KING, SHEDD, and DUNCAN, Circuit Judges.

Dismissed by unpublished PER CURIAM opinion.

Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).

PER CURIAM:

Franklin Antonio Benjamin seeks to appeal the district court’s order accepting the recommendation of the magistrate judge and denying relief on his 28 U.S.C. § 2254 (2000) petition. The order is not appealable unless a circuit justice or judge issues a certificate of appealability. 28 U.S.C. § 2253(c)(1) (2000). A certificate of appealability will not issue absent “a substantial showing of the denial of a constitutional right.” 28 U.S.C. § 2253(c)(2) (2000). A prisoner satisfies this standard by demonstrating that reasonable jurists would find that any assessment of the constitutional claims by the district court is debatable or wrong and that any dispositive procedural ruling by the district court is likewise debatable. *Miller-El v. Cockrell, 537*U.S. 322, 336-38, 123 S.Ct. 1029, 154 L.Ed.2d 931 (2003); *Slack v. McDaniel,*529 U.S. 473, 484, 120 S.Ct. 1595, 146 L.Ed.2d 542 (2000); *Rose v. Lee,*252 F.3d 676, 683-84 (4th Cir.2001). We have independently reviewed the record and conclude that Benjamin has not made the requisite showing. Accordingly, we deny a certificate of appealability and dismiss the *344appeal. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

*DISMISSED.*
Order entered September 20, 2021

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-21-00639-CV

TORIANO MANDRELL KIRK, Appellant

V.

TANITA NASH ATKINS, Appellee

On Appeal from the County Court at Law No. 2

Dallas County, Texas

Trial Court Cause No. CC-19-06824-B

ORDER

By order of September 2, 2021, we directed court reporter Robin 

Washington, Official Court Reporter for County Court at Law No. 2, to file, within 

ten days, either (1) the reporter’s record or (2) written verification no hearings 

were recorded or appellant had not paid or made arrangements to pay for the 

record. To date, Ms. Washington has not responded. Accordingly, we ORDER 

Ms. Washington to file, no later than September 30, 2021, the record or 

requested verification. Because this is an accelerated appeal and the record was 
first due August 2, 2021, we caution Ms. Washington that failure to comply with 

this order may result in an order that she not sit as a reporter until she complies.

We DIRECT the Clerk of the Court to send a copy of this order to the 

Honorable Melissa Jean Bellan, Presiding Judge of County Court at Law No. 2; 

Ms. Washington; and the parties.

/s/ ROBERT D. BURNS, III

CHIEF JUSTICE
#### Johnson *against*Haight and Mathews.

a-notto^al' prom^ssorynoté oafanlTrefusai prored prodadag a?co^ vvltaesa6at' the lh”e origTaa TM21cessaty that no-the migiaai ' should havebeen

. , 'rt°MdedSofeth¿ ■Sal!charfe0rthé théthifd’ day of fhhd’ dayffails then upod^ lS.d- da\

THIS was an action of *assumpsit,*against the • defendants,, as' endorséis of a promissory ’note. ,. The-cause was tried béfore fifr. Justice *Yates,*at the, *Seneca*circuit, in *June,*1816.

The note in question was, executed by *William Low,*dated the 26th of *May,*1315, and payable to the defendants, si? months after date, for. 427 dollars and 19 cents. The.plaintiff proved a demand made at the house of the: maker of the note, upon his agent, (the maker being absent,) on the 30th of *Nóveme her,*next after the date of the note,, and his refusal to pay. • ' , . ^ , The same, witness, who proved the demand and’ refusal, also Pr?ved that he' sent a notice thereof to the defendants by the next after the demand was made, and produced, and offeredjo read, in evidence,'a copy of the, notice which was made at the time ..of- mating the. original. The defendants’ counsel objected to reading the copy, unless notice had been given to °£,produce the original,'but the objection was overruled by the' judge, and the copy-permitted to beread. The plaintiff having-rested his. cause, the counsel for the defendants then moved for a nonsuit, on the ground that, the demand upon the maker of the, note ought to .have been made On the 29 th day of *November,'*next after the ..date of it; but the judge overruled thfe objection, and. the jury, by his direction) found a. verdict-for the .plaintiff.

The case was submitted to the court without argument.

Spencer, J.,

delivered the opinion Of the court."

The first-point maffe by the defendants cannot be maintained; *471it has been decided in this court, that a notice to produce a paper might be proved *by parol.*(3 *Caines,*174. *Turner*v. *Wilson.)*It was held, in *Peytonv*v. *Hallet,*(1 *Caines,*364.,) that an abandonment in writing might be proved by *parol.*Another ground, equally decisive, is, that the copy of a notice retained by a witness is to be regarded as a duplicate original, and sueh duplicate is good evidence, without notice to produce the other, *(Philips on Evidence,*342.)

On the second point, the defendants are entitled to judgment. The third day of grace fell on the 29 th day of *November,*and payment was not demanded of the maker until the 30th. The law-is perfectly settled, that a note must be demanded on the third day of grace, unless that falls on *Sunday,*and then it must be demanded on the second day of grace. (2 *Caines,*343. 16 *East,*250.) Here there is no excuse for delaying the demand on the maker, and there is a palpable want of due diligence, which discharges the endorser.

Judgment for the defendant.
II 

111TH CONGRESS 

1ST SESSION S. 2703 

To renew the temporary suspension of duty on Pigment Yellow 154. 

IN THE SENATE OF THE UNITED STATES 

NOVEMBER 2, 2009 

Mr. WHITEHOUSE (for himself and Mr. REED) introduced the following bill; 

which was read twice and referred to the Committee on Finance 

A BILL 

To renew the temporary suspension of duty on Pigment 

Yellow 154. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. PIGMENT YELLOW 154. 

4 (a) IN GENERAL.—Heading 9902.32.18 of the Har5 monized Tariff Schedule of the United States (relating to 

6 Pigment Yellow 154) is amended by striking the date in 

7 the effective column period and inserting ‘‘12/31/2011’’. 

8 (b) EFFECTIVE DATE.—The amendment made by 

9 subsection (a) applies to goods entered, or withdrawn from 


smartinez on DSKB9S0YB1PROD with BILLS
2 

•S 2703 IS

1 warehouse for consumption, on or after the 15th day after 

2 the date of the enactment of this Act. 

Æ 


smartinez on DSKB9S0YB1PROD with BILLS
Exhibit 32.1**CERTIFICATION**1     Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of1934, as amended (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the UnitedStates Code (18 U.S.C. § 1350), Jean-Loup Romet-Lemonne, M.D., the Chief Executive Officer of IDMPharma, Inc. (the “Company”), and Hervé Duchesne de Lamotte, the Acting Principal Financial andAccounting Officer of the Company, each hereby certifies that, to the best of his knowledge:**1.**The Company’s Quarterly Report on Form 10-Q for the periodended September 30, 2006, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and**2.**The information contained in the Periodic Report fairly presents,in all material respects, the financial condition of the Company at the end of the period covered by the Periodic Report and results of operations of the Company for the period covered by the Periodic Report.Dated: November 14, 2006       /s/ Jean-Loup Romet-Lemonne   /s/ Hervé Duchesne de Lamotte   Jean-Loup Romet-Lemonne, M.D.    Hervé Duchesne de Lamotte  Chief Executive Officer   Acting Principal Financial and Accounting Officer   1 This certification accompanies the Form 10-Q to which it relates, is notdeemed filed with the Securities and Exchange Commission and is not to be incorporated by referenceinto any filing of IDM Pharma, Inc. under the Securities Act of 1933, as amended, or the SecuritiesExchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q),irrespective of any general incorporation language contained in such filing.
[Federal Register Volume 74, Number 203 (Thursday, October 22, 2009)]
[Notices]
[Page 54587]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-25469]



[[Page 54587]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; The Effect of HPV Vaccines on HPV 
Disease.
    Date: October 29, 2009.
    Time: 1:30 p.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6700B Rockledge Drive, 
Bethesda, MD 20817, (Telephone Conference Call)
    Contact Person: Erica L. Brown, PhD, Scientific Review Officer, 
Scientific Review Program, Division of Extramural Activities, NIAID/
NIH/DHHS, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892-7616, 
301-451-2639, <a href="/cdn-cgi/l/email-protection#83e6e1f1ecf4edc3edeae2eae7adedeaebade4ecf5"><span class="__cf_email__" data-cfemail="c2a7a0b0adb5ac82acaba3aba6ecacabaaeca5adb4">[email protected]</span></a>.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: October 16, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-25469 Filed 10-21-09; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Exhibit 4.09

                       LIFSCHULTZ INDUSTRIES, INC.

                     CERTIFICATE OF ELIMINATION FOR
                      CERTIFICATES OF DESIGNATION
                                  FOR
                  SERIES B CONVERTIBLE PREFERRED STOCK
            SERIES C 10% CUMULATIVE NON-VOTING PREFERRED STOCK
            SERIES D 8% CUMULATIVE NON-VOTING PREFERRED STOCK


     LIFSCHULTZ INDUSTRIES, INC., a corporation organized and existing
under the General Corporation Law of the State of Delaware (the
"Corporation"), 

     DOES HEREBY CERTIFY:

     That, pursuant to authority conferred upon the Board of Directors by
the Certificate of Incorporation of the Corporation (as amended), and
pursuant to the provisions of Section 151(g) of Title 8 of the Delaware
Code, the Board of Directors adopted the following resolution effective
as of February 25, 1998, for the purpose of eliminating from the
Corporation's Certificate of Incorporation all matters set forth with
respect to Series B Convertible Preferred Stock, Series C 10% Cumulative
Non-Voting Preferred Stock, and Series D 8% Cumulative Non-Voting
Preferred Stock:

     RESOLVED, that no shares of Series B Convertible Preferred Stock
(designated November 12, 1991), Series C 10% Cumulative Non-Voting
Preferred Stock (designated January 17, 1991), and Series D 8% Cumulative
Non-Voting Preferred Stock (designated January 17, 1991) are currently
outstanding and that no such shares shall be issued by the Corporation
subject to the certificate of designations previously filed by the
Corporation with respect to such Preferred Stock. 

     IN WITNESS WHEREOF, SAID LIFSCHULTZ INDUSTRIES, INC. has caused this
Certificate to be signed by its Chief Executive Officer, this 25th day of
February 1998.

                                    LIFSCHULTZ INDUSTRIES, INC.

                                    By: DAVID K. LIFSCHULTZ     
                                        -------------------
                                        David K. Lifschultz, CEO
#### Carlos Abreu, Appellant, v Betsy Hutchings et al., Respondents.

Decided September 21, 2010

Appeal dismissed, without costs, by the Court of Appeals, sua sponte, upon the ground that the order appealed from does not finally determine the action within the meaning of the Constitution.
<PAGE>

                                                                    EXHIBIT 31.1

                                  CERTIFICATION

I, Emile Loria, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Epimmune Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

     a) designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;

     b) evaluated the effectiveness of the registrant's disclosure controls and
procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and

     c) disclosed in this report any change in the registrant's internal control
over financial reporting that occurred during the registrant's most recent
fiscal quarter that has materially affected or is reasonably likely to
materially affect, the registrant's internal control over financial reporting;
and

5. The registrant's other certifying officer and I have disclosed, based on our
most recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of registrant's board of directors
(or persons performing the equivalent functions):

     a) all significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant's ability to record, process,
summarize and report financial information; and

     b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal control over
financial reporting.

Dated: November 10, 2004

                                  /s/ Emile Loria
                                  ----------------------------------------------
                                  Dr. Emile Loria
                                  President and Chief Executive Officer

                                       1
# Proposed Agreement for Cooperation Between the Government of the United States of America And the Government of the United Arab Emirates Concerning Peaceful Uses of Nuclear Energy

# Memorandum for the Secretary of State [and] the Secretary of Energy

I have considered the proposed Agreement for Cooperation Between the Government of the United States of America and the Government of the United Arab Emirates Concerning Peaceful Uses of Nuclear Energy, along with the views, recommendations, and statements of the interested agencies.

I have determined that the performance of the Agreement will promote, and will not constitute an unreasonable risk to, the common defense and security. Pursuant to section 123 b. of the Atomic Energy Act of 1954, as amended (42 U.S.C. 2153(b)), I hereby approve the proposed Agreement and authorize the Secretary of State to arrange for its execution.

                    The Secretary of State is authorized and directed to publish this determination in the                     *Federal Register*.                

[FR Doc. E9-12582

Billing code 4710-10-P